Prime Medicine Inc [NASDAQ: PRME] gained 12.45% or 0.34 points to close at $3.07 with a heavy trading volume of 6670684 shares.
The daily chart for PRME points out that the company has recorded 5.86% gains over the past six months.
If we look at the average trading volume of 2.43M shares, PRME reached to a volume of 6670684 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Prime Medicine Inc [PRME]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PRME shares is $7.69 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PRME stock is a recommendation set at 1.73. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Prime Medicine Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 27, 2025. The new note on the price target was released on May 20, 2025, representing the official price target for Prime Medicine Inc stock.
The Price to Book ratio for the last quarter was 3.77, with the Price to Cash per share for the same quarter was set at 1.10.
Trading performance analysis for PRME stock
Prime Medicine Inc [PRME] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.86. With this latest performance, PRME shares gained by 157.98% in over the last four-week period, additionally plugging by 5.86% over the last 6 months – not to mention a rise of 5.14% in the past year of trading.
Prime Medicine Inc [PRME]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Prime Medicine Inc [PRME] shares currently have an operating margin of -5369.68% and a Gross Margin at -69.34%. Prime Medicine Inc’s Net Margin is presently recorded at -5252.50%.
Return on Equity for this stock declined to -63.17%, with Return on Assets sitting at -63.17%.
Prime Medicine Inc [PRME]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRME. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Prime Medicine Inc go to 18.30%.
An analysis of Institutional ownership at Prime Medicine Inc [PRME]
The top three institutional holders of PRME stocks are: ALPHABET INC. with ownership of 15.06 million shares, which is approximately 12.6375%. ARK INVESTMENT MANAGEMENT LLC, holding 6.13 million shares of the stock with an approximate value of $$31.49 million in PRME stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $$31.25 million in PRME stock with ownership which is approximately 5.1002%.
